Loading...
XNAS
PTIXW
Market cap3mUSD
Jun 12, Last price  
0.05USD
1D
-10.00%
1Q
1,223.53%
Name

Protagenic Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.82%
Rev. gr., 5y
%
Revenues
0k
00018,721,00036,982,000113,884,00069,089,00040,026,00085,00000000000000
Net income
-6m
L+10.50%
-7,900,000-2,234,000-94,470677,000-4,149,000-115,766,000-29,470,000-19,727,000-1,027,000-1,079,000-476,000-2,275,826-2,259,636-2,557,531-1,766,797-2,794,913-4,986,639-3,601,556-5,000,497-5,525,344
CFO
-4m
L+13.84%
1,870,000-842,000-44,000931,000-5,210,0004,355,000-3,015,000-11,250,000-324,000-790,000-378,000-1,140,319-1,380,089-1,071,188-487,990-1,348,779-2,798,614-1,993,814-3,703,776-4,216,517
Earnings
Aug 12, 2025

Profile

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
URL
https://protagenic.com/
IPO date
Dec 18, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑06
Income
Revenues
Cost of revenue
5,604
4,555
3,558
Unusual Expense (Income)
NOPBT
(5,604)
(4,555)
(3,558)
NOPBT Margin
Operating Taxes
46
Tax Rate
NOPAT
(5,604)
(4,555)
(3,604)
Net income
(5,525)
10.50%
(5,000)
38.84%
(3,602)
-27.78%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,964
BB yield
-81.78%
Debt
Debt current
344
Long-term debt
Deferred revenue
Other long-term liabilities
1,014
Net debt
(1,838)
(4,056)
(7,634)
Cash flow
Cash from operating activities
(4,217)
(3,704)
(1,994)
CAPEX
(150)
(2)
Cash from investing activities
2,803
4,775
1,597
Cash from financing activities
1,964
FCF
(5,480)
(4,677)
(3,606)
Balance
Cash
1,838
4,056
7,979
Long term investments
Excess cash
1,838
4,056
7,979
Stockholders' equity
(36,432)
(30,891)
(26,454)
Invested Capital
37,445
34,559
33,716
ROIC
ROCE
EV
Common stock shares outstanding
4,900
4,345
4,318
Price
0.49
-50.51%
0.99
-38.13%
1.60
-71.12%
Market cap
2,401
-44.18%
4,301
-37.74%
6,909
-66.16%
EV
563
245
(726)
EBITDA
(5,553)
(4,527)
(3,558)
EV/EBITDA
0.20
Interest
137
Interest/NOPBT